Agios Pharmaceuticals (NASDAQ:AGIO) Trading Up 4%

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 4% on Friday . The stock traded as high as $44.63 and last traded at $44.13. 217,078 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 818,024 shares. The stock had previously closed at $42.45.

Analyst Ratings Changes

AGIO has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. The Goldman Sachs Group raised their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. Finally, StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 29th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $50.67.

Agios Pharmaceuticals Stock Performance

The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -7.16 and a beta of 0.77. The firm’s 50-day simple moving average is $36.78 and its two-hundred day simple moving average is $29.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period last year, the company earned ($1.47) EPS. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -2.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the sale, the director now owns 137,396 shares in the company, valued at approximately $3,785,259.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $41,000. China Universal Asset Management Co. Ltd. grew its stake in Agios Pharmaceuticals by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 5,040 shares during the period. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $210,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 942 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Agios Pharmaceuticals by 31.8% during the 4th quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 2,900 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.